北京荨麻疹治疗好医院 http://baidianfeng.39.net/a_zhiliao/210116/8595950.htmlSCI
7Jan
Pamrevlumab,ananti-connectivetissuegrowthfactortherapy,foridiopathicpulmonaryfibrosis(PRAISE):aphase2,randomised,double-blind,placebo-controlledtrial(LancetRespMed,IF:22.9)
RicheldiL,FernándezPérezER,CostabelU,etal.Pamrevlumab,ananti-connectivetissuegrowthfactortherapy,foridiopathicpulmonaryfibrosis(PRAISE):aphase2,randomised,double-blind,placebo-controlledtrial.TheLancetRespiratoryMedicine;8:25-33.
Correspondenceto
rofLucaRicheldi,UnitàOperativaComplessadiPneumologia,FondazionePoliclinicoUniversitarioA.GemelliIRCCS,UniversitàCattolicadelSacroCuore,Rome,Italyluca.richeldi
policlinicogemelli.it
Summary背景
BackgroundConnectivetissuegrowthfactor(CTGF)isasecretedglycoproteinthathasacentralroleintheprocessoffibrosis.Thisstudywasdesignedtoassessthesafety,tolerability,andefficacyofpamrevlumab(FG-),afullyre